DNLI

Denali Therapeutics Inc.

Price

$25.69

return (12m)

73.52%

p/e

-8.91

p/bv

5.46

DIVIDEND YIELD

0.00%

DNLI price

Denali Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment DNLI

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

9.41%

3 months

33.11%

1 year

73.52%

2 years

7.27%

5 years

-47.51%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals DNLI

Valuation

P/E

-8.91

Sector -4.38

Industry -4.38

P/BV

5.46

Sector 2.02

Industry 2.02

P/Revenue (PSR)

1,266.15

Sector -4.40

Industry -4.40

EV/EBITDA

-30.52

Sector -263.09

Industry -263.09

EV/EBIT

-29.47

Sector -702.90

Industry -702.90

P/EBITDA

-8.65

Sector -4.39

Industry -4.39

P/EBIT

-8.40

Sector -4.73

Industry -4.73

P/Total Assets

3.94

Sector 1.49

Industry 1.49

P/Net Current Assets

10.57

Sector -11.70

Industry -11.70

P/Working Capital

6.87

Sector -3.19

Industry -3.19

EPS

-2.74

Sector -2.14

Industry -2.14

BVPS

4.47

Sector 1.85

Industry 1.85

Efficiency

Gross Margin

97.50%

Sector 36.74%

Industry 36.74%

EBITDA Margin

-3,501.67%

Sector -16,244.81%

Industry -16,244.81%

EBIT Margin

-3,626.11%

Sector -4,202,541.34%

Industry -4,202,541.34%

Operating Margin

-100.00%

Sector -38.22%

Industry -38.22%

Net Profit Margins

-100.00%

Sector -39.69%

Industry -39.69%

Asset Turnover

0.00

Sector 0.03

Industry 0.03

Profitability

ROE

-61.24%

Sector -65.14%

Industry -65.14%

ROA

-44.17%

Sector -65.53%

Industry -65.53%

ROIC

-144.03%

Sector -2,103.35%

Industry -2,103.35%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

8.37

Sector 2.90

Industry 2.90

Net Debt / EBITDA

5.64

Sector -6.07

Industry -6.07

Net Debt / EBIT

5.44

Sector -8.26

Industry -8.26

Net Debt / Equity

-0.85

Sector -1.07

Industry -1.07

Gross Debt / Equity

0.00

Sector -0.05

Industry -0.05

Equity/Assets

0.72

Sector 0.41

Industry 0.41

Liabilities/Assets

0.28

Sector 0.39

Industry 0.39

Growth

5Y Revenue CAGR

-40.59%

Sector -

Industry -

5Y Earnings CAGR

11.97%

Sector -

Industry -

Fundamentals DNLI

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
DNLI Denali Therapeutics Inc.	$25.69	73.35%	0.00%	-8.91	5.46	-61.24%	-100.00%
JNJ Johnson & Johnson	$273.41	58.46%	2.02%	29.66	7.34	24.76%	21.48%
PFE Pfizer Inc.	$28.24	21.45%	6.54%	34.62	1.75	5.07%	6.80%
ABBV AbbVie Inc.	$265.97	33.11%	2.73%	70.02	-74.53	-106.44%	9.81%
NVO Novo Nordisk A/S	$46.48	-9.14%	4.09%	11.13	5.91	53.11%	35.32%
MRK Merck & Co. Inc.	$152.20	87.95%	2.45%	106.68	8.06	7.56%	4.77%
AZN AstraZeneca PLC	$164.95	4.92%	2.07%	22.98	4.77	20.74%	17.02%
BMY Bristol-Myers Squibb Company	$67.61	46.95%	3.93%	14.06	5.85	41.59%	18.87%
ZTS Zoetis Inc.	$76.68	-48.52%	2.77%	11.89	9.88	83.10%	27.49%
REGN Regeneron Pharmaceuticals Inc.	$840.84	43.05%	0.45%	19.09	2.61	13.65%	27.86%
AMGN Amgen Inc.	$442.36	55.11%	2.39%	25.30	18.93	74.80%	22.95%
HALO Halozyme Therapeutics Inc.	$107.62	56.06%	0.00%	27.82	80.17	288.14%	24.86%
MCK McKesson Corporation	$853.71	27.85%	0.38%	22.42	-79.15	-352.96%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$552.06	41.60%	0.00%	29.26	6.36	21.76%	35.00%
CAH Cardinal Health Inc.	$234.85	58.85%	0.88%	31.61	-19.89	-62.92%	0.67%
HRMY Harmony Biosciences Holdings Inc.	$39.93	9.67%	0.00%	12.18	2.21	18.14%	18.89%
BIIB Biogen Inc.	$221.56	63.02%	0.00%	37.04	1.64	4.43%	8.32%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

DNLI Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Denali Therapeutics

Denali Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

13 years

Founded: 2013

2017

Time since IPO - 9 years

291

Employees

Denali Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $4.56 billion, with shareholders equity totaling $835.18 million.

The company employs approximately 291 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Denali Therapeutics Inc. reported $3.60 million in revenue, generating net income of $-511.45 million.

Key financial metrics include a P/E ratio of -8.91, a price-to-book (P/B) ratio of 5.46, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker DNLI.

Market cap

$4.56 billion

Net worth

$835.18 million

$835,180,000.00

Assets

$1.16 billion

$1,157,950,000.00

Total Shares Outstanding

187.00 million

187,000,000

Average Daily Trading Volume

$1.82 million

$1,816,438.00

Sector

Health Care

Industry

Biotechnology

DNLI

DNLI revenue and profits

Financial Results DNLI

DRAG THE FRAME TO SEE MORE DATA

DNLI cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$853.71 22,07% (12M)

P/E

22.42

0.38%

ROE

-352.96%

P/BV

-79.15

CAH - Cardinal Health

$234.85 55,51% (12M)

P/E

31.61

0.88%

ROE

-62.92%

P/BV

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12M)

P/E

29.66

2.02%

ROE

24.76%

P/BV

7.34

ABBV - AbbVie

$265.97 31,23% (12M)

P/E

70.02

2.73%

ROE

-106.44%

P/BV

-74.53

MRK - Merck & Co.

$152.20 86,97% (12M)

P/E

106.68

2.45%

ROE

7.56%

P/BV

8.06

AZN - AstraZeneca

$164.95 5,00% (12M)

P/E

22.98

2.07%

ROE

20.74%

P/BV

4.77

PFE - Pfizer

$28.24 21,16% (12M)

P/E

34.62

6.54%

ROE

5.07%

P/BV

1.75

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$853.71 22,07% (12 M)

P/L

22.42

0.38%

ROE

-352.96%

P/VP

-79.15

CAH - Cardinal Health

$234.85 55,51% (12 M)

P/L

31.61

0.88%

ROE

-62.92%

P/VP

-19.89

JNJ - Johnson & Johnson

$273.41 57,54% (12 M)

P/L

29.66

2.02%

ROE

24.76%

P/VP

7.34

ABBV - AbbVie

$265.97 31,23% (12 M)

P/L

70.02

2.73%

ROE

-106.44%

P/VP

-74.53

MRK - Merck & Co.

$152.20 86,97% (12 M)

P/L

106.68

2.45%

ROE

7.56%

P/VP

8.06

AZN - AstraZeneca

$164.95 5,00% (12 M)

P/L

22.98

2.07%

ROE

20.74%

P/VP

4.77

PFE - Pfizer

$28.24 21,16% (12 M)

P/L

34.62

6.54%

ROE

5.07%

P/VP

1.75

Frequently Asked Questions

What is the price of Denali Therapeutics (DNLI) today?

A cotação de Denali Therapeutics (DNLI) hoje está em US$ 25.69, com uma variação de 73.52% em relação ao último ano. A cotação de Denali Therapeutics (DNLI) iniciou o ano negociando na casa dos US$ 16.51 e hoje está em US$ 25.69. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Denali Therapeutics (DNLI) e dados de ações do Ibovespa e mercados internacionais.

Quando Denali Therapeutics (DNLI) paga dividendos?

Denali Therapeutics (DNLI) não distribuiu dividendos no último ano.

Is Denali Therapeutics (DNLI) a good investment?

Atualmente, Denali Therapeutics (DNLI) está cotada a US$ 25.69, com um P/L de -8.91, representando um desvio de -1,088% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 73.52 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 73.52%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Denali Therapeutics (DNLI) stock?

Investir em ações de Denali Therapeutics (DNLI) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Denali Therapeutics (DNLI) yield today?

A rentabilidade de Denali Therapeutics (DNLI) foi de 9.41% no último mês, 73.52% no último ano e -47.51% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Denali Therapeutics (DNLI) hoje, o investimento total seria de US$ 2,569.00, com base na cotação atual de US$ 25.69.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 4,457.73
Em 5 anos: US$ 1,348.47
Em 10 anos: US$ 2,569.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

DNLI

Denali Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment DNLI

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING DNLI WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Denali Therapeutics

Denali Therapeutics Inc.

United States

13 years

2017

291

PROFIT X PRICE DNLI

Financial Results DNLI

DNLI cash flow

Asset, Revenue and Profit Growth - DNLI

DNLI balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions